Cisplatin treatment modulates Annexin A1 and inhibitor of differentiation to DNA 1 expression in cervical cancer cells

Author(s)

Prates, Janesly ^[1] ; Moreli, Jusciele Brogin ^{[2, 3]} ; Gimenes, Alexandre Dantas ^[3] ; Biselli, Joice Matos ^[1] ; Garcia Pires D'Avila, Solange Correa ^[4] ; Sandri, Silvana ^[5] ; Poliselli Farsky, Sandra Helena ^[5] ; Rodrigues-Lisoni, Flavia Cristina ^{[1, 6]} ; Oliani, Sonia Maria ^{[3, 1]}

Affiliation

^[1] Sao Paulo State Univ, Unesp, Inst Biosci Humanities & Exact Sci Ibilce, Campus Sao Jose do Rio Preto, Sao Jose Do Rio Preto, SP - Brazil

^[2] Faceres Sch Med, Sao Jose Do Rio Preto, SP - Brazil

^[3] Univ Fed Sao Paulo, UNIFESP, Postgrad Struct & Funct Biol, Sao Paulo, SP - Brazil

^[4] Sao Jose do Rio Preto Sch Med FAMERP, Dept Pathol, Sao Jose Do Rio Preto, SP - Brazil

^[5] Sao Paulo Univ USP, Fac Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo - Brazil

^[6] Sao Paulo State Univ, Unesp, Ilha Solteira Sch Engn FEIS, Campus Ilha Solteira, Ilha Solteira, SP - Brazil

• Document type: Journal article
• Source: BIOMEDICINE & PHARMACOTHERAPY; v. 129, SEP 2020.
• Web of Science Citations: 0

Abstract

Cisplatin (Cis) is a choice chemotherapy approach to cervical cancer by inducing DNA adducts and subsequent apoptosis. We have investigated the effects of Cis on Annexin A1 (ANXA1) and inhibitor of DNA binding 1 (ID1) proteins expression to elucidate further mechanisms of Cis actions. Human cervical tissue samples from twentyfour patients, with Cervical Intraepithelial Neoplasia (CIN, stage I, II and III), were evaluated to quantified ANXA1 and ID1 expressions. In vitro, human epidermoid carcinoma of the cervix (SiHa cell line) were treated with Annexin A1 peptide (ANXA1(2-26)), Cis or Cis + ANXA1(2-26) to evaluate cell proliferation and migration, cytotoxicity of treatments as well as ANXA1 and ID1 modulations by mRNA and protein expression. Our findings showed expression of ID1 and ANXA1 proteins in tissue samples from Cervical Intraepithelial Neoplasia (CIN) patients, with intense immunological identification of ID1 in the CIN III stage. In SiHa cells, treatments with Cis alone or Cis + ANXA1(2-26), increase mRNA expressions of the ANXA1 and reduced the ID1. In agreement, Cis + ANXA1(2-26) enhanced ANXA1 protein expression and Cis or Cis + ANXA1(2-26) abolished ID1 protein expression. Cell proliferation was reduced after treatment with ANXA1(2-26) peptide and more significant after Cis or Cis + ANXA1(2-26) treatments. These two last treatments reduced cell viability, by inducing late apoptosis, and impaired cell migration. Together, our data highlight endogenous ANXA1 is involved in Cis therapy for cervical cancer. (AU)

• FAPESP's process: 16/02012-4 - Evaluation of the immunomodulatory activity of annexin A1 protein in the regulation of inflammatory disorders of the gastrointestinal system: studies in vivo and in vitro experimental models
• Grantee: Sonia Maria Oliani
• Support Opportunities: Regular Research Grants